Regeneron highlights DUPIXENT, cemdisiran and EYLEA HD growth drivers
The update says DUPIXENT continues to drive growth and expand into new indications, cemdisiran is nearing launch for myasthenia gravis, and EYLEA HD uptake is described as robust. It also references collaboration talks with Sanofi and upcoming data readouts for cemdisiran.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.